Severing the scar supply line: CAR-T in chronic kidney disease

IF 20.4 1区医学 Q1 CELL & TISSUE ENGINEERING

Cell stem cell Pub Date : 2025-09-04 DOI:10.1016/j.stem.2025.08.002

Longwei Liu, Yingxiao Wang

引用次数: 0

Abstract

CAR-T cell therapy is rapidly being extended to target various pathophysiological processes beyond cancer. In this issue of Cell Stem Cell, Zhao et al. engineered PDGFRβ-specific CAR-T cells in vivo to selectively target extracellular matrix-producing cells in kidney fibrosis,¹ opening new opportunities for treating fibrotic diseases with precision immunotherapy.

查看原文本刊更多论文

切断疤痕供给线：CAR-T治疗慢性肾脏疾病

CAR-T细胞疗法正在迅速扩展到针对癌症以外的各种病理生理过程。在这一期的《细胞干细胞》中，Zhao等人在体内设计了pdgfr β特异性CAR-T细胞，选择性地靶向肾纤维化的细胞外基质生成细胞，1为精确免疫治疗纤维化疾病开辟了新的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell stem cell 生物-细胞生物学

CiteScore

37.10

自引率

2.50%

发文量

151

审稿时长

42 days

期刊介绍： Cell Stem Cell is a comprehensive journal covering the entire spectrum of stem cell biology. It encompasses various topics, including embryonic stem cells, pluripotency, germline stem cells, tissue-specific stem cells, differentiation, epigenetics, genomics, cancer stem cells, stem cell niches, disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging, therapeutic applications, regenerative medicine, clinical insights, research policies, ethical considerations, and technical innovations. The journal welcomes studies from any model system providing insights into stem cell biology, with a focus on human stem cells. It publishes research reports of significant importance, along with review and analysis articles covering diverse aspects of stem cell research.